Announced details
Cancer immunology, third-line treatment of pancreatic cancer, and other cancer areas.
The primary endpoint of the 3-month progression-free survival rate was achieved in Groups 1 and 2 of the CBP501 Phase 2 clinical trial.
The document states that the joint research on IDO/TDO dual inhibitors with Shizuoka University of Art and Science, the AI-based joint drug discovery research with Intage Healthcare, and the CBS9106 licensing agreement with Stemline were terminated in June 2025, with all rights returned.
Patents for IDO/TDO dual inhibitors granted in Japan and the United States. Patent numbers and expiry dates: not disclosed.
2-2-1 Otemachi, Numazu, Shizuoka, Japan
Upfront payments under the CBS9106 agreement were ¥10 million in December 2014 and ¥5 million in August 2018. Technology advisory fees totaled ¥702 million from December 2014 through June 2021.
No business revenue was recorded for the fiscal year ending June 2026. Operating loss was ¥1,358 million, ordinary loss was ¥1,307 million, and net loss was ¥1,308 million. The document states that basic research on CBS9106 will have no short-term impact on operating performance.
The company does not address Offering price.
The International Agency for Research on Cancer (IARC) GLOBOCAN2018
ECIS (European Cancer Information System) Globocan 2022 data
NCCN Clinical Practice Guidelines in Oncology, 2021, Version 2
ESMO2020
Anticancer Research
Oncologist
Cancer Res Clin Oncol
Cancer Medicine
J Clin Oncol
Therapeutics and Clinical Risk Management
American Society of Health-System Pharmacists (ASHP)
| Item | Details |
|---|---|
| Names of Products / Services Covered | CBP501, CBT005, CBS9106, CBP-A08, IDO/TDO dual inhibitor |
| Relationship with the Company | The document states that the joint research on IDO/TDO dual inhibitors with Shizuoka University of Art and Science, the AI-based joint drug discovery research with Intage Healthcare, and the CBS9106 licensing agreement with Stemline were terminated in June 2025, with all rights returned. |
| Contract Value | Upfront payments under the CBS9106 agreement were ¥10 million in December 2014 and ¥5 million in August 2018. Technology advisory fees totaled ¥702 million from December 2014 through June 2021. |
| Contract Date | CBS9106 out-licensed: December 2014. Expansion of licensed territories: August 2018. Agreement terminated and all rights returned: June 2025. |
| Applicable area | Cancer immunology, third-line treatment of pancreatic cancer, and other cancer areas. |
| Registration number and expiry date | Patents for IDO/TDO dual inhibitors granted in Japan and the United States. Patent numbers and expiry dates: not disclosed. |
| Location | 2-2-1 Otemachi, Numazu, Shizuoka, Japan |
| Location scale | 19 employees (14 in research and development, 5 in administration) |
| Quantitative Effects | The primary endpoint of the 3-month progression-free survival rate was achieved in Groups 1 and 2 of the CBP501 Phase 2 clinical trial. |
| Impact on Business Performance | No business revenue was recorded for the fiscal year ending June 2026. Operating loss was ¥1,358 million, ordinary loss was ¥1,307 million, and net loss was ¥1,308 million. The document states that basic research on CBS9106 will have no short-term impact on operating performance. |
| Source | The International Agency for Research on Cancer (IARC) GLOBOCAN2018, ECIS (European Cancer Information System) Globocan 2022 data, NCCN Clinical Practice Guidelines in Oncology, 2021, Version 2, ESMO2020, Anticancer Research, Oncologist, Cancer Res Clin Oncol, Cancer Medicine, J Clin Oncol, Therapeutics and Clinical Risk Management, American Society of Health-System Pharmacists (ASHP) |
Items this document does not state (7)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.To explain the company's business, development pipeline, the status of its application to initiate a Phase 3 trial of CBP501 in Europe, its operating performance and financial position, and its funding policy to investors and shareholders.